NCT07412288招募中1 期
A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-579 in Healthy Adult Participants
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 96
- 试验地点
- 1
- 主要终点
- Incidence of adverse events
研究概览
简要总结
This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
盲法说明
The Sponsor is also masked to treatment allocation.
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Participants with a weight of at least 50 kg if male or 40 kg if female, and a body mass index (BMI) between 18.0 and 32.0 kg/m² (inclusive) at Screening.
- •Participants must be willing and able to read, understand, and sign an informed consent form (ICF) which includes compliance with requirements and restrictions listed in the ICF and in this protocol.
- •Participants must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
排除标准
- •Participants who have a clinically relevant history of respiratory, gastrointestinal (GI), renal, hepatic, hematological, lymphatic, endocrinological, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, ophthalmological, or connective tissue diseases or disorders.
- •Participants who have a clinically relevant surgical history (e.g. surgery of the GI tract that could interfere with the PK of the trial medication) Note: prior appendectomy or cholecystectomy is not exclusionary.
- •Participants with a history of alcohol or substance abuse within the previous 2 years.
- •Participants who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
- •Participants who test positive for alcohol and drugs of abuse at Screening and on admission to the CRU.
- •Participants who have acute GI symptoms at the time of Screening or on admission to the CRU (e.g. nausea, vomiting, diarrhea, heartburn).
- •Participants whose results from clinical laboratory safety tests are outside the local reference range at Screening and on admission to the CRU.
- •Participants who have previously received KT-579 in another cohort in this study.
- •Participants who have been dosed with any investigational drug or device in a clinical study within 30 days or 5 half-lives (whichever is longer) of KT-579/placebo administration.
- •Male participants who do not agree to refrain from sperm donation from admission to the CRU to 90 days after the last dose of study drug.
- •Male participants (and their partners of childbearing potential) and female participants who do not agree to the contraception requirements as specified in the clinical protocol.
- •Female participants who are pregnant, lactating, or breast-feeding or plan to become pregnant (including ova donation) within 30 days of last study drug administration.
- •Female participants with a positive or undetermined pregnancy test at Screening and on admission to the CRU.
研究组 & 干预措施
KT-579
Active Comparator
Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of KT-579.
干预措施: KT-579 (Drug)
Placebo
Placebo Comparator
Each participant receives either a single oral dose (SAD) or multiple oral doses (MAD) of matched placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Incidence of adverse events
时间窗: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
Incidence of serious adverse events
时间窗: From enrollment through the safety follow-up visit on either Day 14 (SAD) or Day 38 (MAD)
次要结局
- Maximum concentration (Cmax): observed maximum concentrations derived from plasma concentration data(Day 1 (SAD); Day 1, Day 7, and Day 14 (MAD))
- Time to maximum concentration (Tmax): observed time to achieve maximum concentrations derived from plasma concentration data(Day 1 (SAD); Day 1, Day 7, and Day 14 (MAD))
- Area under the curve (AUC0-last): Area under the plasma concentration-time curve calculated using non-compartmental analysis from time zero to the last observed timepoint(Day 1 (SAD); Day 1, Day 7, and Day 14 (MAD))
- Area under the curve (AUC0-infinity): Area under the plasma concentration-time curve calculated using non-compartmental analysis from time zero to infinite time(Day 1 (SAD))
- Area under the curve (AUC0-tau): Area under the plasma concentration-time curve calculated using non-compartmental analysis from time zero to end of the dosing interval(Day 1, Day 7, and Day 14 (MAD))
- Terminal elimination half-life (t1/2): elimination half-life calculated using non-compartmental analysis(Day 1 (SAD) and Day 14 (MAD))
- Fraction excreted: Fraction of drug excreted unchanged in urine(Day 14 (MAD))
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 InjectionNCT07334249Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.80
招募中
1 期
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid TumorsNCT07334119Myeloid Therapeutics60
招募中
1 期
Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RN5681 in Healthy VolunteersNCT07347678Ikaria Bioscience Pty Ltd60
招募中
1 期
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid TumorsNCT07265921Jiangsu Simcere Pharmaceutical Co., Ltd.232
招募中
1 期
SAD and MAD Study of AKB-9090 in Healthy Adult ParticipantsNCT07429006Akebia Therapeutics44